Sage Therapeutics price target raised to $22 from $20 at Truist

Truist raised the firm’s price target on Sage Therapeutics to $22 from $20 but keeps a Hold rating on the shares. The firm’s survey of Zurzuvae targeting 40 obstetricians suggests that awareness is high, and OBs expressed overall favorable view of Zurzuvae’s risk/benefit profile, the analyst tells investors in a research note, adding that 21% stated that they would offer Zurzuvae as first-line Tx for the “majority “or “vast majority” of their PPD patient. Truist adds however that the high list price of $15,900 was a source of strong push back, raising concerns that the use of Zurzuvae may be limited to PPD patients who require rapid resolution.